Prurigo Nodularis Treatment Market
Number of pages: 100 | Report Format: PDF | Published date: April 18, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.5 billion |
|
Market Size Value in 2031 |
US$ 3.4 billion |
|
CAGR |
3.7% |
|
Base Year For Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Product, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global prurigo nodularis treatment market was valued at US$ 2.5 billion in 2022 and is expected to register a revenue CAGR of 3.7% to reach US$ 3.4 billion by 2031.
Prurigo Nodularis Treatment Market Fundamentals
Prurigo nodularis is a skin condition characterized by the development of hard, itchy, raised bumps or nodules on the skin that can range in size from a few millimeters to several centimeters in diameter. The causes of prurigo nodularis are not fully understood, but it is believed to be related to chronic skin irritation or inflammation. Treating prurigo nodularis involves a combination of topical and oral medications to reduce inflammation and alleviate itching. Some commonly used treatments include topical corticosteroids, topical calcineurin inhibitors, oral antihistamines, phototherapy, and medications such as gabapentin, pregabalin, and naltrexone. In addition to medication, prurigo nodularis treatment guidelines include avoiding triggers such as harsh soaps, scratchy clothing, and extreme temperatures can help reduce the severity of symptoms. Regular moisturizing can also help prevent skin dryness and reduce the risk of flare-ups.
[56756]
Prurigo Nodularis Treatment Market Dynamics
The growing prevalence of prurigo nodularis is one of the primary drivers of the prurigo nodularis treatment market revenue growth. The market revenue for prurigo nodularis treatment is fueled by the availability of a wide range of treatment options. These include topical and oral medications. Multiple treatment options are available, so patients and healthcare providers can choose the most appropriate treatment for their specific needs. Ongoing research is into developing a new treatment for prurigo nodularis, such as monoclonal antibodies and other biologic therapies. These new treatments have the potential to improve patient outcomes significantly. Moreover, advances in medical technology have led to the development of new and innovative treatments for prurigo nodularis. For example, phototherapy has become more advanced recently, and more options are now available for patients.
New treatments are expected to increase the demand for prurigo nodularis. There is a growing awareness of prurigo nodularis among patients and healthcare providers. As more people become aware of the condition and its symptoms, they are more likely to seek treatment. This is expected to drive market revenue growth as more patients can access and afford treatment.
However, the treatments for prurigo nodularis can have side effects, such as skin irritation, nausea, and drowsiness. These side effects can limit patient adherence to treatment, thus restricting the prurigo nodularis treatment market revenue growth. There is currently no definitive set of diagnostic criteria for prurigo nodularis. This can make it difficult for healthcare providers to diagnose the condition accurately.
Prurigo Nodularis Treatment Market Ecosystem
The global prurigo nodularis treatment market is analyzed from three perspectives: product, distribution channel, and region.
Prurigo Nodularis Treatment Market by Product
[74544]
Based on the product, the global prurigo nodularis treatment market is segmented into antihistamines, corticosteroids, capsaicin cream, emollients, and others.
The corticosteroids segment accounted for the largest prurigo nodularis treatment market revenue share. Corticosteroids are highly effective in reducing inflammation and itching associated with prurigo nodularis. They are often the first-line treatment for mild to moderate cases of the condition. Corticosteroids are widely available and accessible to patients. They are available in various formulations, such as creams, ointments, lotions, and injections, and can be purchased over the counter or with a prescription. Corticosteroids have been used to treat prurigo nodularis for many years and have a well-established safety profile. They are generally considered safe when used as directed and under medical supervision. Corticosteroids, such as biological therapies, are generally less expensive than some of the newer treatment options for prurigo nodularis. This makes them a more affordable option for patients and healthcare providers, boosting segmental revenue growth.
The antihistamines segment accounted for a considerable revenue share of the prurigo nodularis treatment market in 2022. Antihistamines are a class of medications commonly used to treat allergies, but they can also be used to treat prurigo nodularis. They work by blocking the release of histamines, chemicals in the body that cause itching, swelling, and inflammation. Antihistamines are popular for prurigo nodularis treatment, as they have a well-established safety profile and are generally well-tolerated by patients. Antihistamines are often used with other medications for prurigo nodularis treatment, which can increase their revenue share in the market. For example, they may be prescribed topical corticosteroids to provide additional relief for patients.
Prurigo Nodularis Treatment Market by Distribution Channel
Based on the distribution channel, the global prurigo nodularis treatment market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
The retail pharmacies segment dominated the prurigo nodularis treatment market growth with the highest revenue share. Retail pharmacies are easily accessible to patients and offer a convenient option for patients to purchase medications prescribed by their healthcare providers. Patients can walk into a retail pharmacy and fill their prescriptions on the spot without waiting for their medication to be delivered or going to a specialty pharmacy. Retail pharmacies carry many medications for different conditions, including those used to treat prurigo nodularis. Patients can find a variety of medications, including corticosteroids, antihistamines, and other topical treatments, at their local retail pharmacy. Retail pharmacies often offer competitive pricing for medications, which can be especially important for patients who do not have health insurance coverage or have high deductibles. Additionally, many retail pharmacies offer discounts, coupons, and other savings programs to help make medications more affordable for patients. Patients often have a trusted relationship with their local retail pharmacy and pharmacist, which can provide a sense of comfort and familiarity when purchasing medications. Patients can ask their pharmacist questions about their medications and receive personalized advice and recommendations.
The online pharmacies segment is expected to register lucrative revenue CAGR during the forecast period from 2023 to 2031. Online pharmacies offer the convenience of ordering medications from the comfort of one's own home without having to leave the house. This can be especially important for patients with mobility issues and people who live in rural areas or have busy schedules. Online pharmacies are accessible to patients worldwide, regardless of their location. This can be particularly important for patients who may not have access to a local retail pharmacy or specialty pharmacy. Online pharmacies often have a wider selection of medications and treatments for prurigo nodularis than traditional retail pharmacies. This can provide patients with more options for treatment and increase the likelihood of finding an effective treatment for their condition. Online pharmacies often offer competitive pricing for medications, as they do not have the same overhead costs as traditional brick-and-mortar pharmacies. Additionally, online pharmacies may offer discounts, coupons, and other savings programs to make medications more affordable for patients.
Prurigo Nodularis Treatment Market by Region
Based on region, the global prurigo nodularis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America has an increasing prevalence of prurigo nodularis treatment market size in terms of revenue generation. North America has a relatively high prevalence of prurigo nodularis, which drives demand for effective treatments. According to the National Organization for Rare Disorders in the U.S., an estimated 72 per 100,000 people, or 87,634 people aged 18 to 64, are affected by prurigo nodularis yearly. There is growing awareness of prurigo nodularis among healthcare providers and patients, leading to increased diagnosis rates and treatment demand. North America has a well-developed healthcare infrastructure, including advanced hospitals, clinics, and research institutions. This infrastructure supports the development and distribution of new treatments for prurigo nodularis. Patients have a growing preference for topical treatments for prurigo nodularis, which are often associated with fewer side effects than systemic treatments. There is a significant investment in research and development of new treatments for prurigo nodularis in North America. This investment drives the development of more effective drugs and therapies with fewer side effects than existing treatments.
Asia Pacific accounts for the fastest revenue CAGR in terms of the prurigo nodularis treatment market during the forecast period. The rising incidence of prurigo nodularis is expected to increase with the growing aging population and rising pollution levels. This is driving the demand for prurigo nodularis treatment in the region. The development of new treatments for prurigo nodularis, including topical and systemic medications, is expected to drive the market revenue share. For example, calcineurin inhibitors, such as tacrolimus and Pimecrolimus, have shown promising results in treating prurigo nodularis. Rising healthcare expenditure in the Asia Pacific region and the increasing availability of medical facilities are expected to drive the market for prurigo nodularis treatment. With increasing awareness about prurigo nodularis among patients and healthcare providers, there is likely to be an increase in the diagnosis and treatment of this condition. This is expected to drive the market revenue share for prurigo nodularis treatment.
Prurigo Nodularis Treatment Competitive Landscape
The prominent players operating in the global prurigo nodularis treatment market are:
Prurigo Nodularis Treatment Strategic Developments
Treating prurigo nodularis involves a combination of topical and oral medications to reduce inflammation and alleviate itching. Some commonly used treatments include topical corticosteroids, topical calcineurin inhibitors, oral antihistamines, phototherapy, and oral medications such as gabapentin, pregabalin, and naltrexone.
The expected size of the global prurigo nodularis treatment market in 2031 is US$ 3.4 billion.
Based on region, North America accounts for the largest market revenue share, followed by Europe, and Asia Pacific is expected to be the fastest-growing region during the forecast period.
The global prurigo nodularis treatment market revenue growth is expected to be 3.7%.
The corticosteroids segment dominates the global prurigo nodularis treatment market with the largest revenue share.
*Insights on financial performance are subject to the availability of information in the public domain